Acne mRNA vaccine
Sponsors
Sanofi Pasteur Inc., Sanofi Pasteur, a Sanofi Company
Conditions
Acne
Phase 1
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
RecruitingNCT06316297
Start: 2024-04-05End: 2028-11-30Target: 800Updated: 2026-08-21
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
RecruitingNCT07013747
Start: 2025-07-03End: 2030-03-13Target: 228Updated: 2026-07-09
A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the
safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age
Not yet recruitingCTIS2025-521740-38-00
Target: 70Updated: 2026-07-29